Point of Care Technologies for Nutrition, Infection, and Cancer for Global Health (PORTENT)
Project Number5U54EB034654-02
Contact PI/Project LeaderERICKSON, DAVID CARL Other PIs
Awardee OrganizationCORNELL UNIVERSITY
Description
Abstract Text
1.0 Overall Abstract
We propose the establishment of PORTENT – “Point-of-Care Technologies for Nutrition, Infection and Cancer
for Global Health” centered at Cornell University in partnership with Columbia and McGill Universities.
The recent Lancet Diagnostic Commission report states that the “diagnostic gap is most severe at the level of primary
health care, in which only about 19% of populations in low-income and lower-middle-income countries have
access to the simplest of diagnostic tests … People who are poor, marginalized, young, or less educated have the
least access to diagnostics.” Developing PoC devices for these populations is challenging. The needs are unique,
the users have disparate qualifications, the path to commercialization is different, the settings have variable
infrastructure, the regulatory agencies have distinctive requirements, and the stakeholders are diverse. The
PORTENT Center is unique as it (1) focuses on primary health care globally; (2) addresses the needs of the
most vulnerable in the US and internationally; and (3) enables a broad range of diagnostic technologies to be
validated on a global scale while simultaneously developing expertise and building capacity internationally
to have the most impact even beyond the center. The center builds on our decades of international experience in
validation, deployment, and commercialization of POC systems and incorporates clinical validation and satellite
technology sites across four continents enabling testing on diverse populations and with a unique set of users.
Our approach is fundamentally enabled by 5 key differentiable elements: (1) A rigorous approach to Needs
Assessment through the establishment of an annual Global PoC Needs Assessment Consensus developed by a
Needs Assessment Advisory Board; (2) The ability to validate PoC technologies on an exceptionally broad range
of established populations and biospecimens in New York City, Ecuador, India, and Uganda; (3) The
establishment of a “Lab-to-Market accelerator for Global Health Point of Care Technologies” to provide
commercialization and tech-to-market support for PORTENT projects; (4) Unique training opportunities and
knowledge transfer workshops for healthcare workers in LMICs on the use of PoC devices and clinical rotations
at our international sites for PoC developers; (5) Access to the team’s network of industrial partners, diagnostics
companies, regulatory experts, venture capital groups, and domestic & international non-governmental
organizations. Illustrative of what we will fund through PORTENT, we describe four “Year 1” projects that (1) enable
early screening of cervical cancer, (2) determination of iron status enabling anemia screening, (3) combined HIV and
multiplexed detection of sexually transmitted diseases, and (4) broader, cheaper, and more accurate malaria testing.
By the end of year 5, PORTENT will: initiate 20 independent PoC technology projects (with 30% from outside
US), engage ~ 15 teams in the Global Health Lab-to-Market accelerator program, train 30 health care workers
from LMICs on use of PoC technologies, and provide >20 clinical rotations for technology developers.
Public Health Relevance Statement
Point of Care Technologies for Nutrition, Infection and Cancer for Global Health (PORTENT)
1.0 Overall
Narrative
Focusing on the largest clinical needs where access to better diagnostics can have the largest worldwide impact,
we propose the formation of PORTENT – “Point-of-Care Technologies for Nutrition, Infection and Cancer for
Global Health” centered at Cornell University in partnership with Columbia and McGill Universities. At full
capacity we will advance between 6 and 7 parallel PoC technology teams through: human validation at one of
our network of clinical sites spread across four continents, user and developer training and rotations, and
commercialization. The PORTENT Center is differentiable from others as it (1) focuses on primary health care
globally; (2) addresses the needs of the most vulnerable in the US and internationally; and (3) enable a broad
range of diagnostic technologies to be validated on a global scale while simultaneously developing expertise and
building capacity internationally to have the most impact.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAfricaAnemiaAreaAsiaBiological SciencesBusinessesCOVID-19 pandemicCapitalCervical Cancer ScreeningClinicalCommunicable DiseasesConsensusDevelopmentDevice or Instrument DevelopmentDevicesDiagnosticDiagnostic testsDirect CostsDisparateEcologyEcuadorEducational workshopElementsEngineeringEntrepreneurshipEventFundingGenerationsHIVHealth PersonnelHealthcare SystemsHumanIncubatorsIndiaIndustrializationInfectionInfrastructureInstitutionInternationalIronKnowledgeLeadershipLettersLow incomeMalariaMalignant NeoplasmsMarketingMindModelingNeeds AssessmentNetwork-basedNew York CityNongovernmental OrganizationsNorth AmericaPatientsPersonsPoint of Care TechnologyPopulationPopulation HeterogeneityPositioning AttributePrimary CarePrimary Health CareQualifyingRegulatory AffairsReportingRotationSexually Transmitted DiseasesSiteSouth AmericaSystemTechnologyTestingTherapeuticTrainingTranslationsTravelUgandaUnited StatesUnited States National Institutes of HealthUniversitiesValidationVeteransclinical research sitecollegecommercializationdiagnostic technologiesearly screeningexperienceglobal healthhealth care disparityinterestlow and middle-income countriesmarginalizationmarginalized populationmultiplex detectionnext generationnutritionpoint of carepoint-of-care diagnosticsprogramsresearch and developmentscreeningstatisticstechnology developmenttechnology validationtraining opportunity
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
872612445
UEI
G56PUALJ3KT5
CCV3WG2JG248
D4H1NV4APKP3
ELS2M3C6V2S5
EQA8NBEN9WD5
FFAZGE9NH3M8
K6JRCJJXFET1
M8FBSLHASMT3
P4LRVQT1H4K5
PJUVN8AT5416
RT1JPM9UMGM5
ZBMGUAZYFGC4
ZMP8BDLJTUW9
Project Start Date
13-September-2023
Project End Date
31-July-2028
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$1,310,994
Direct Costs
$1,095,957
Indirect Costs
$215,037
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$910,994
2024
John E. Fogarty International Center for Advanced Study in the Health Sciences
$400,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U54EB034654-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U54EB034654-02
Patents
No Patents information available for 5U54EB034654-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U54EB034654-02
Clinical Studies
No Clinical Studies information available for 5U54EB034654-02
News and More
Related News Releases
No news release information available for 5U54EB034654-02
History
No Historical information available for 5U54EB034654-02
Similar Projects
No Similar Projects information available for 5U54EB034654-02